Please assess the completion status of the following clinical trial:

Trial Title: A Phase III, Double-blind Study to Assess Safety and Efficacy of an RSV Maternal Unadjuvanted Vaccine, in Pregnant Women and Infants Born to Vaccinated Mothers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Maternal participants~* Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.~* Participants who give written or witnessed/thumb printed informed consent after the study has been explained, and before any study specific procedures are performed, as per local regulations regulatory requirements.~* Age 18 to 49 years, inclusive, at the time of study intervention.~* Pre-pregnancy BMI 17.0 to 39.9 kg/m2, inclusive.~* In good general maternal health as established by medical history and clinical examination before entering into the study.~* Singleton pregnancy (including instances where the singleton pregnancy derives from a vanishing twin syndrome).~* At 24\^0/7 to 34\^0/7 weeks of gestation at the time of study vaccination (Visit 1), as established by:~* last menstrual period (LMP) date corroborated by first or second trimester ultrasound examination (U/S) i.e. at or before 28 weeks of gestation.~* 1st or 2nd trimester U/S only, if LMP is unknown/uncertain~* Certain LMP, corroborated by an U/S performed after 28 weeks of gestation is also acceptable.~* No fetal genetic abnormalities (based on genetic testing, if performed).~* No significant congenital malformations, as assessed by fetal anomaly ultrasound scan conducted at or beyond 18 weeks of gestation.~* Willing to provide cord blood.~* Who do not plan to give their child for adoption.~* Who plan to reside in the study area for at least one year after delivery.~* Willing to have the infant followed-up after delivery for a period of 12 months.~Infant participants~* Live-born from the study pregnancy.~* If required per local regulations/guidelines, re-signed (confirmed) written or witnessed/thumb printed informed consent for study participation of the infant obtained from the infant's mother and/or father and/or LAR, before performing any study specific procedure. OR, if permitted by local regulation, documented verbal consent for infant's participation obtained from the parent(s)/LAR(s) at birth, followed by written consent obtained by (or before) Visit 2-newborn.~Exclusion Criteria:~Maternal participants Medical conditions~* History of allergic disease or reactions likely to be exacerbated by any component of the RSV vaccine~* Hypersensitivity to latex~* Significant complications in the current pregnancy:~* Gestational hypertension unless blood pressure it is controlled and maintained in the normal range (\<140mmHg and \<90mmHg) through diet and/or antihypertensive medications~* Gestational diabetes not controlled by medication, diet and/or exercise~* Pre-eclampsia~* Eclampsia~* Intrauterine Growth Restriction/Fetal Growth Restriction~* Placenta previa~* Placental abruption, placenta accreta/percreta/increta, chorioamnionitis or any abnormalities that can impair the maternal-fetal circulation~* Polyhydramnios~* Oligohydramnios~* Preterm labour or history of preterm labour in the current pregnancy~* Any intervention to prevent preterm delivery or medical treatment for suspected preterm delivery, including administration of systemic corticosteroids for fetal lung maturation~* Cholestasis~* Other pregnancy-related complications (per investigator's judgement)~* Significant structural abnormalities of the uterus or cervix~* History of 2 or more prior stillbirths or neonatal deaths/history of 2 or more preterm births at ≤34 weeks gestation/3 or more consecutive spontaneous abortions~* Known HIV infection (as per serological tests performed during the current pregnancy)~* Known or suspected HBV or HCV infection~* Known or suspected infection during the current pregnancy with Toxoplasma, Parvovirus B19, Syphilis, Zika, Rubella, Varicella, CMV or primary genital Herpes Simplex~* Active infection with tuberculosis~* Known or suspected impairment of the immune system~* Current autoimmune disorder for which the participant has received immune-modifying therapy within 6 months before study vaccination, or plans administration through delivery~* Lymphoproliferative disorder or malignancy within 5 years before study vaccination~* Acute or chronic clinically significant abnormality or poorly controlled pre-existent co-morbidities or any other clinical conditions that might pose additional risk to the participant due to participation in the study~* Any conditions that may interfere with participant's ability to comply with study procedures or receipt of prenatal care~* Any condition which would increase the risks of study participation to the unborn infant~Prior/Concomitant therapy~* Prior receipt of an RSV vaccine in the current pregnancy~* Use of any investigational/non-registered product other than the study vaccine/product as described below, or planned use during the period :~* For a drug, vaccine or medical device: from 29 days before the dose of study vaccine~* For immunoglobulins: 3 months before the dose of study vaccine/product.~The exception to this is investigational products administered in the setting of a pandemic which may be allowed following delivery~* Planned administration/administration of any vaccine from 29 days before the dose of study vaccine or planned administration through delivery, except:~* Seasonal influenza vaccines, tetanus vaccines, dTpa/Tdap - alone vaccines, dTpa/Tdap vaccines that also contain other antigens, Hepatitis B vaccines, and COVID-19 vaccines all of which may be administered according to standard of care ≥15 days before or after study vaccination~* Administration of immunoglobulins (except anti-Rh0D IG, which may be administered at any time), blood products or plasma derivatives within 3 months before study vaccination or planned administration through delivery~* Administration of immune-modifying therapy within 6 months before the study vaccination, or planned administration through delivery. This includes but is not limited to:~* Azathioprine, mycophenolate mofetil, 6-mercaptopurine, cyclosporine, tacrolimus, monoclonal or polyclonal antibodies~* Prednisone ≥5 mg/day or equivalent for ≥14 days; Inhaled, intra-articular/intra-bursal and topical steroids are allowed~* Corticosteroids administered for fetal lung maturation~Prior/Concurrent clinical study experience~- Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product~Other exclusions~* Alcoholism or substance use disorder within the past 24 months based on DSM-5 criteria~* A local condition that precludes injection of the study vaccine/product or precludes assessment of local reactogenicity~* Consanguinity of maternal participant and her partner (second degree cousins or closer)~* Any study personnel or their immediate dependants, family or household members~Infant participants~* Concurrently participating in another clinical study, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product~* Any condition which would increase the risks of study participation to the infant~* Child in care.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 49 Years
- Healthy Volunteers: t

Study Arms:
- RSV MAT Group - Mother (Type: EXPERIMENTAL): Maternal participants received a single dose of the RSV MAT vaccine administered at Day 1 in this study.
- Placebo Group - Mother (Type: PLACEBO_COMPARATOR): Maternal participants received a single dose of placebo administered at Day 1 in this study.
- RSV MAT Group - Infant (Type: NO_INTERVENTION): This group consisted of infants born to mothers (from RSV MAT Group - Mother) who received a single dose of RSV MAT vaccine during pregnancy.
- Placebo Group - Infant (Type: NO_INTERVENTION): This group consisted of infants born to mothers (from Placebo Group - Mother) who received a single dose of placebo during pregnancy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval